Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml

Serum Isoform [−2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2–10 ng/ml: A Multicentric European Study

(2013) Massimo Lazzeri et al.   EUROPEAN UROLOGY

Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy

(2013) Vincenzo Scattoni et al.   JOURNAL OF UROLOGY

The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy

(2012) Xavier Durand et al.   BJU INTERNATIONAL

Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers

(2012) Matteo Ferro et al.   CLINICA CHIMICA ACTA

Multicenter Evaluation of [-2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer

(2012) C. Stephan et al.   CLINICAL CHEMISTRY

Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum [-2]Proprostate-Specific Antigen-Based Prostate Health Index for Detection of Prostate Cancer

(2012) C. Stephan et al.   CLINICAL CHEMISTRY

Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay

(2012) Jens Hansen et al.   EUROPEAN UROLOGY

Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer

(2012) Jeffrey J. Tosoian et al.   JOURNAL OF UROLOGY

Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

(2012) Sisto Perdonà et al.   PROSTATE

Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting

(2011) Giorgio Guazzoni et al.   EUROPEAN UROLOGY

Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer

(2011) Marco Auprich et al.   EUROPEAN UROLOGY

Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer

(2011) Giorgio Guazzoni et al.   EUROPEAN UROLOGY

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

(2011) William J. Catalona et al.   JOURNAL OF UROLOGY

ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program

(2011) Sumit Isharwal et al.   UROLOGY

Pre-analytical in-vitro stability of [-2]proPSA in blood and serum

(2010) Axel Semjonow et al.   CLINICAL BIOCHEMISTRY

External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome

(2010) Marco Auprich et al.   EUROPEAN UROLOGY

A note on adaptive Bonferroni and Holm procedures under dependence

(2009) W. Guo   BIOMETRIKA

Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study

(2009) Roderick C.N. van den Bergh et al.   BJU INTERNATIONAL

Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program

(2009) Jeffrey J. Tosoian et al.   JOURNAL OF UROLOGY

Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus StatementStandard Operating Procedure Integration Working Group

(2008) Melissa K. Tuck et al.   JOURNAL OF PROTEOME RESEARCH